Premier Recognizes JOURNAVX™ By Vertex As A Game-Changer In Acute Pain Treatment

Vertex Pharmaceuticals announced it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading healthcare improvement company. This recognition was awarded for Vertex’s novel pain therapy, JOURNAVX™ (suzetrigine), an oral, non-opioid treatment developed for moderate-to-severe acute pain.

“Premier proudly acknowledges Vertex’s outstanding commitment to advancing health care. Their innovative product, recognized at our 2025 Innovation Celebration, reflects our shared mission to drive cost-efficiency, operational excellence and improved patient outcomes. We applaud Vertex for their invaluable contributions to health care,” said Bruce Radcliff, Senior Vice President, Supply Chain, at Premier. 

JOURNAVX™ is a highly selective NaV1.8 pain signal inhibitor that offers a new approach to pain relief without the risks associated with opioids. Its designation as a breakthrough innovation reflects its potential to change pain management practices by delivering effective relief while avoiding the side effects and dependency issues common with traditional opioid treatments.

“We are honored to be recognized at Premier’s 2025 Innovation Celebration. This reflects our unwavering commitment to bringing innovative medicines, like JOURNAVX — a non-opioid and the first new class of pain medicine approved in decades — to patients with significant unmet need,” said Duncan McKechnie, Executive Vice President and Chief Commercial Officer at Vertex.

Premier’s Innovation Celebration, which is in its 14th year, recognizes innovative healthcare products after careful appraisals by clinicians, physicians and supply chain professionals. JOURNAVX TM was chosen among approximately 120 nominees, and it will be awarded at the Breakthroughs 2025 Conference and Exhibition on July 15.